XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Revenues $ 717.4 $ 666.2
Operating expenses:    
Salaries and benefits 215.2 202.2
Supplies 188.8 188.4
Professional and medical fees 82.6 74.6
Lease expense 21.4 21.4
Other operating expenses 54.1 45.6
Cost of revenues 562.1 532.2
General and administrative expenses 33.2 32.0
Depreciation and amortization 33.7 33.7
Transaction and integration costs 17.4 12.5
Net loss on disposals, consolidations and deconsolidations 1.5 10.5
Equity in earnings of unconsolidated affiliates (2.7) (3.3)
Litigation settlements (1.8) 3.0
Other income, net (2.0) (0.8)
Total operating expenses 641.4 619.8
Operating income 76.0 46.4
Interest expense, net (47.3) (46.8)
Income (loss) before income taxes 28.7 (0.4)
Income tax (expense) benefit (4.4) 1.6
Net income 24.3 1.2
Less: Net income attributable to non-controlling interests (36.7) (26.1)
Net loss attributable to Surgery Partners, Inc. $ (12.4) $ (24.9)
Net loss per share attributable to common stockholders:    
Basic (in USD per share) $ (0.10) $ (0.20)
Diluted (in USD per share) [1] $ (0.10) $ (0.20)
Weighted average common shares outstanding:    
Basic (shares) 125,972 125,206
Diluted (shares) [1] 125,972 125,206
[1] The impact of potentially dilutive securities for all periods were not considered because the effect would be anti-dilutive.